Please assess the completion status of the following clinical trial:

Trial Title: Cluster Headache Cortivazol Injection (CHCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient age, man or woman whose age is between 18 and 65 included~* patient who signed a free express and informed consent~* patient with cluster headache, episodic or chronic according to the criteria of International Headache Society (ICHD-II)~* patient with more than two episodes of CH per day~* patient with a normal medical examination~Exclusion Criteria:~* patient not affiliated with a social security scheme (or beneficiary entitled)~* patient with another diagnosis ICHD-II,and being unable to differentiate CH attacks from its other cranial pain~* patient of CH having started his episodic active period more than 30 days ago~* patient with a contra-indication to verapamil~* patient with a known allergy to cortivazol~* patient with anticoagulant therapy or having a bleeding disorder~* patient unable to complete the schedule crisis~* patient non-compliant or unable to follow the research protocol~* women without contraception, pregnant, or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): subcutaneous injection of Cortivazol ALTIM, 3,375mg
- 2 (Type: PLACEBO_COMPARATOR): PROAMP, subcutaneous serum physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).